The David Sackler suffering from a case of mistaken identity has grown a beard, wears a baseball cap in public and fears being attacked, although he looks nothing like the pharmaceutical industry ...

David Sackler, who served on Purdue’s board from 2012 to 2018, and Kathe Sackler, a board member from 1990 to 2018 and a former vice president, faced heated questioning from the House Oversight ...

He’s David Sackler -- but not THAT David Sackler. A New Jersey executive says in a new lawsuit that media outlets turned his life into a real downer by running his photo alongside stories about ...

David and Kathe Sackler, members of the family that owns Purdue Pharma, the maker of OxyContin, testified via video to a House Oversight Committee hearing on Dec. 17, 2020.

David Sackler, president of a New Jersey nutrition-consulting firm, filed a libel suit after the New York Post wrongly identified him as the David Sackler who is a member of the billionaire New ...

David Sackler, whose family owns Purdue Pharma, is defending the company and his family against what he describes as “vitriolic hyperbole,” saying they’re not to blame for the opioid crisis ...

In response to questions from a House oversight panel last week, David Sackler, who served on Purdue’s board from 2012 to 2018, testified that neither he, nor others, anticipated vast litigation ...

David Sackler testified Tuesday the settlement payments from his family would be drawn from their family trust — in which he is one of the beneficiaries — but not their personal assets. According to a ...

One day last spring, Ryan Hampton had a secret meeting with David Sackler, whose family’s company, Purdue Pharma, stood accused of helping to precipitate the opioid crisis.

“No,” David Sackler responded when Maloney asked whether the family was cashing out, leaving less money for plaintiffs in opioid lawsuits. “I also am very angry,” Kathe Sackler said.

In this image from House Television, David Sackler, a member of the family that owns Purdue Pharma testifies via video to a House Oversight Committee hearing Thursday, Dec. 17, 2020.